Results 1 to 10 of about 204,699 (375)
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Drugs, 2023 Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been ...
F. Bonella +2 more
semanticscholar +1 more source
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.
PLoS ONE, 2021 Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi +11 more
doaj +1 more source
International Journal of Molecular Sciences, 2023 Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati +6 more
semanticscholar +1 more source
Pulmonary Circulation, 2021 The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan +7 more
doaj +1 more source
Frontiers in Medicine, 2022 Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou +8 more
doaj +1 more source
Medicina Clínica (English Edition), 2022 Idiopathic pulmonary fibrosis is defined as a chronic progressive fibrosing interstitial pneumonia of unknown etiology. There are intrinsic and extrinsic risk factors that could favor the development of the disease in individuals with a genetic predisposition.
Francisco, León-Román +2 more
+8 more sources
The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis
Antioxidants, 2022 The mortality rate of idiopathic pulmonary fibrosis (IPF) increases yearly due to ineffective treatment. Given that the lung is exposed to the external environment, it is likely that oxidative stress, especially the stimulation of DNA, would be of ...
Jiahui Zhu +10 more
doaj +1 more source
BMC Pulmonary Medicine, 2023 Background Following COVID-19 infection, some patients acquired lung injury and fibrosis. Idiopathic pulmonary fibrosis is characterized by lung fibrosis.
Deniz Kızılırmak +3 more
doaj +1 more source
Cough in Idiopathic Pulmonary Fibrosis [PDF]
Frontiers in Rehabilitation Sciences, 2021 Chronic cough is experienced by most patients with idiopathic pulmonary fibrosis (IPF). It is often the first symptom and is associated with reduced quality of life, increased rates of depression and anxiety, more severe physiological impairment, and disease progression.
Jennifer Mann +11 more
openaire +4 more sources
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Frontiers in Pharmacology, 2022 Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality. With an increase in life expectancy, the economic burden of IPF is
Qian Mei +4 more
semanticscholar +1 more source